Atyr PHARMA (NASDAQ:ATYR – Get Free Report) and Quince Therapeutics (NASDAQ:QNCX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Atyr PHARMA and Quince Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Atyr PHARMA | 0 | 0 | 4 | 0 | 3.00 |
| Quince Therapeutics | 0 | 0 | 2 | 2 | 3.50 |
Atyr PHARMA currently has a consensus target price of $19.25, indicating a potential upside of 529.08%. Quince Therapeutics has a consensus target price of $8.50, indicating a potential upside of 318.72%. Given Atyr PHARMA’s higher possible upside, equities analysts plainly believe Atyr PHARMA is more favorable than Quince Therapeutics.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Atyr PHARMA | $350,000.00 | 733.88 | -$50.39 million | ($0.94) | -3.26 |
| Quince Therapeutics | N/A | N/A | -$31.39 million | ($1.24) | -1.64 |
Quince Therapeutics has lower revenue, but higher earnings than Atyr PHARMA. Atyr PHARMA is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
61.7% of Atyr PHARMA shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 3.7% of Atyr PHARMA shares are owned by insiders. Comparatively, 16.8% of Quince Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Atyr PHARMA and Quince Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Atyr PHARMA | N/A | -79.44% | -59.16% |
| Quince Therapeutics | N/A | -53.27% | -22.73% |
Risk and Volatility
Atyr PHARMA has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.
Summary
Quince Therapeutics beats Atyr PHARMA on 7 of the 13 factors compared between the two stocks.
About Atyr PHARMA
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
About Quince Therapeutics
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Receive News & Ratings for Atyr PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.
